net dbt
new near-term horizon
increas po deal time tighten
hope come end deal process po
alongsid pbm primer reiter buy rate view best
way invest pbm market attractive/risk reward roughli
pf ep also increas price object post-deal
newco assum deal close gener better total growth rate return
profil new po equat ep slightli
still low end multi-year averag take account higher
multipl aetna manag care compani
post-deal focu valu joint entiti
assum near-term approv depart justic remain state
think key focu detail overview new compani
better posit manag total cost care member close gap care
think opportun could come better align two compani data
analyt inform well expans current establish joint
strategi compani work year on-going partnership
also think remain signific opportun reshap store
healthcar servic someth outlin store futur
seri link link although expect broader plan like come
compani host analyst day first half
bull case still point meaning upsid potenti
given upcom integr two compani think near-term
blend multipl right valuat metric howev newco show sign
success integr abil gener multipl expans clearli place
base blend multipl aetna newco potenti trade
entiti run-rat effect pace estim
could yield much upsid vs current trade level potenti downsid
support joint compani cash flow gener
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest healthcar compani
unit state provid retail mail
specialti pharmaci dispens servic
pharmaci benefit upon complet
acquisit aetna would becom one
vertic integr publicli trade
healthcar compani base
buy rate driven transform
vertic integr aetna assum deal
close stabl free cash flow appeal
valuat think compani deal aetna
provid ampl short-term long-term synergi
opportun provid clear way extract
valu retail franchis stabl
free cash flow three busi
allow compani gener outsiz
return equiti next year
exhibit blend multipl would yield meaning upsid current trade level
return po
factset bofa merril lynch global research
exhibit current pariti rx suppli chain well larg cap retail larg cap hmo sector forward price-to-earnings basi
rx suppli chain includ esrx
larg cap retail includ kr
larg cap hmo includ ci
price object base ep estim multipl
five-year averag absolut basi toward lower end
histor rang also repres bigger discount vs
last five year discount reflect margin pressur across core pharmaci
servic retail pharmaci segment uncertainti around drug price
downsid risk po risk amazon anoth disrupt forc enter
suppli chain failur close aetna transact close gener expect
synergi aetna transact grow competit risk pharmaci benefit
market slow prescription/insur trend upsid risk po
potenti prescript volum pickup faster stronger expect synergi
aetna improv front-end perform
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
